Gilead stops another CD47 study, this time in acute myeloid leukemia

Gilead stopped a Phase III study of its CD47 an­ti­body ma­grolimab in pa­tients who have acute myeloid leukemia with TP53 mu­ta­tions, the com­pa­ny an­nounced Tues­day.

In a press state­ment, the com­pa­ny said, “Based on an ad hoc analy­sis, and fol­low­ing re­view by an in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee, Gilead con­clud­ed that ma­grolimab is un­like­ly to demon­strate a sur­vival ben­e­fit in AML with TP53 mu­ta­tions com­pared to stan­dard of care.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.